Success rates among patients undergoing rFVIIIFc ITI. ∗Successful tolerization was defined as attaining negative inhibitor titer (<0.6 BU/mL), rFVIIIFc IR ≥66% of expected IR, and t_1/2 ≥7 hours; †total values exceed 100% following rounding; ‡partial success was defined as receiving 48 weeks of ITI treatment and achieving a negative inhibitor status and 1 normal PK parameter (IR ≥1.32 IU/dL per IU/kg OR t_1/2 ≥7 hours); §patient achieved a negative inhibitor titer and normal IR; ||patients were considered to have failed ITI if there was reduction of inhibitor titer <20% within a 6-month period following the initial 12 weeks of rFVIIIFc ITI, presence of a positive inhibitor (≥0.6 BU/mL) after 48 weeks of ITI with rFVIIIFc, or a negative-inhibitor titer without achieving either an IR ≥1.32 IU/dL per IU/kg (representing ≥66% of expected IR) or t_1/2 ≥7 hours after 48 weeks of rFVIIIFc ITI; and ¶2 (12.5%) had a titer change of <20% from weeks 12 to 36, 2 (12.5%) had completed 48 weeks of ITI and maintained a positive inhibitor titer, and 1 (6.3%) completed 48 weeks of ITI and achieved a negative inhibitor titer without attaining either normal PK parameter (IR or t_1/2 ≥7 hours).